News

Akston Initiates Clinical Trial of Once-Weekly GLP-1 Weight-Management Therapy for Cats

BEVERLY, Mass., Nov. 25, 2025 /PRNewswire/ -- Akston, the Biotech Built for Pets, announced today the start of a clinical study at Cornell University College of Veterinary Medicine to evaluate its once-weekly GLP-1 weight-management therapy for cats. The trial will assess the therapy over a roughly three-month period in client-owned domestic cats affected by excess weight. Excess weight is one of the most common health issues in cats today. According to the Association for Pet Obesity Prevention (APOP)1, 61% of U.S. cats...
Read more...

Wasabi Introduces High-Performance Class and Expands into Silicon Valley to Take on AI’s Rising Data Storage Costs

BOSTON--(BUSINESS WIRE)--Wasabi Technologies, the Hot Cloud Storage company, expanded further into artificial intelligence with the unveiling of Wasabi Fire, a high-performance storage class that supports AI workloads, available beginning in early 2026. Wasabi has also opened a new storage region in San Jose, Calif., as part of its relationship with IBM Cloud. The milestones reinforce Wasabi’s push to expand its role in AI infrastructure as demand for scalable, high-performance and cost-efficient cloud...
Read more...

RevBio® Receives First FDA Approval for a “Bone Glue” to Treat Extremity Fractures in a Clinical Trial

LOWELL, Mass.--(BUSINESS WIRE)--RevBio® announced today that TETRANITE, the company’s first of its kind regenerative “bone glue” has been approved for a 20-patient pilot study to measure the biomaterial’s safety and efficacy to treat complex, multi-fragmented wrist fractures including those that involve articular surfaces. Read More>>
Read more...

Elizabeth Banks on Her Tips for Packing Light, the Destination That ‘Blew Her Mind,’ and Her Biggest Airplane Pet Peeve

With Elizabeth Banks

Go-to drink order on a plane?  Skyhigh Spritz. Our bubbly is fantastic, but on JetBlue, we also have our sauvignon blanc, our rosé, and our malbec, which is a great red, and they're all delicious. They just make it so easy to have a little cocktail on hand and sort of settle into what hopefully is going to be a really fun trip. Read More>>
Read more...

CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (ICANS), announced today that it has been awarded a $2.25 million National Institutes of Health (NIH) grant, the fourth NIH grant totaling $7.85 million in five years. Read More>>
Read more...

New ScorePlay and Wasabi Technologies partnership gives sports organizations the ultimate platform for smarter, faster fan content

New York City, 10.22.2025 - ScorePlay, the leading AI-powered MAM/DAM designed for sports, and Wasabi Technologies, the hot cloud storage company, today announced a strategic partnership that redefines how sports organizations manage, collaborate on, and distribute their content. “The future of sports media is open, intelligent, and instant. We’re empowering every organization to harness AI and cloud technology to manage their content with our bespoke industry offering. By removing the traditional barriers of cost and technical complexity, Wasabi and ScorePlay are giving...
Read more...

Sportel: AI changing the game for content creation and fan engagement

The panel, made up of Tixier, Matthew Quinn, vice president of media for English soccer giants Liverpool FC, and cloud storage firm Wasabi Technologies’ chief marketing officer, Michael Welts, discussed how sports organizations were quickly adopting AI into their content strategies in the race to keep fans engaged in different time zones and attract new fans globally. Read More>>
Read more...

In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I

SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated re-dosing of a patient with a gene modified therapeutic product candidate. The patient in Immusoft's first-in-human clinical study has now received two doses – separated by 18 months1 – of ISP-001 to treat mucopolysaccharidosis type I (MPS I), with an excellent safety and tolerability profile, to date. Moreover, Immusoft continues to observe positive results in this ongoing...
Read more...

Candidly Launches AI-Powered Financial Guidance Platform

NEW YORK--(BUSINESS WIRE)--Candidly today announced the launch of the Candidly Intelligence Center, an enterprise-grade deterministic AI system that delivers tailored financial insights extensible across multiple financial domains. The Candidly Intelligence Center is a sophisticated multi-agentic backend system that orchestrates specialized AI agents across distinct financial domains that span both the liabilities and assets side of the balance sheet. When combined with a user-facing interface — like Cait, Candidly's conversational AI tool —...
Read more...

Quthero’s Clinical Trial Results Published in Prestigious Medical Journal

TORONTO, ONTARIO, CANADA, September 29, 2025 /EINPresswire.com/ -- Quthero, a pioneering biotech company advancing regenerative medicine through its proprietary Q-peptide platform technology, announced today that the results of their recent clinical trial have been published in the September 2025 issue of the peer-reviewed Journal of Drugs in Dermatology. Quthero's breakthrough technology enables complete regeneration of a patient's natural tissue with minimal scarring. Read More>>
Read more...